PMID- 12777994
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20191107
IS  - 1541-2016 (Print)
IS  - 1533-4058 (Linking)
VI  - 11
IP  - 2
DP  - 2003 Jun
TI  - Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ 
      hybridization in mammary Paget disease and underlying carcinoma.
PG  - 120-4
AB  - HER-2/Neu overexpression is seen in 20% to 30% of invasive breast carcinomas and 
      has been reported in as many as 80% of high-grade infiltrating carcinomas. 
      Earlier studies have suggested that 100% of the tumor cells in mammary Paget 
      disease show overexpression of HER-2 protein. We undertook this study to assess 
      HER-2 status of mammary Paget disease and of the underlying breast carcinoma, 
      when present, by immunohistochemistry (IHC) and fluorescence in situ 
      hybridization (FISH). Formalin-fixed, paraffin-embedded tissue from 20 cases of 
      mammary Paget disease were analyzed for HER-2 status by IHC and FISH. IHC for 
      estrogen receptor (ER) was also performed. The patients ranged in age from 34 to 
      88 years, with a mean age of 62 years. Eighty percent of the cases showed strong 
      overexpression (3+) of HER-2 protein by IHC, and all of these cases showed more 
      than 5-fold amplification of the HER-2 gene by FISH. The remaining 4 cases, which 
      were negative for HER-2/Neu by IHC, showed no amplification by FISH. All of the 
      latter cases expressed ER, whereas no case that overexpressed HER-2 expressed ER. 
      Sixteen cases had an underlying tumor, which was in situ in 6 cases. The 
      underlying tumors were identical to the Paget disease with respect to their 
      HER-2/Neu overexpression by both IHC and FISH. HER-2 overexpression was 
      identified in 80% of our cases of Paget disease. There was 100% concordance 
      between HER-2 protein overexpression by immunohistochemistry and gene 
      amplification in both the Paget and the underlying tumor. Moreover, all of the 
      cases negative for HER-2 overexpression expressed ER, whereas those positive for 
      HER-2 did not.
FAU - Anderson, Joseph M
AU  - Anderson JM
AD  - Department of Pathology, Rush Medical College, Chicago, Illinois 60612, USA.
FAU - Ariga, Reshma
AU  - Ariga R
FAU - Govil, Hema
AU  - Govil H
FAU - Bloom, Kenneth J
AU  - Bloom KJ
FAU - Francescatti, Darius
AU  - Francescatti D
FAU - Reddy, Vijaya B
AU  - Reddy VB
FAU - Gould, Victor E
AU  - Gould VE
FAU - Gattuso, Paolo
AU  - Gattuso P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Proteins/analysis
MH  - Paget's Disease, Mammary/*chemistry/pathology
MH  - Receptor, ErbB-2/*analysis
MH  - Receptors, Estrogen/analysis
EDAT- 2003/06/05 05:00
MHDA- 2004/04/24 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 10.1097/00129039-200306000-00005 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):120-4. doi: 
      10.1097/00129039-200306000-00005.